Dyax halts mid-stage study of rare disease drug
Dyax halts mid-stage study of rare disease drug (Reuters) - Biopharmaceutical company Dyax Corp will halt a mid-stage study of its experimental drug to treat a rare disorder caused due to swelling of the skin, after it failed to show significant improvement compared with a placebo. The news sent the companys shares down as much as 16 percent to $1.80 after markets closed on Thursday. The drug, ecallantide, is Dyaxs lead compound. It is already being sold in the United States since February 2010 under the trade name Kalbitor to treat acute attacks of hereditary angioedema. ... //news.yahoo.com/dyax-halts-mid-stage-study-rare-disease-drug-202845116--finance.html
Create Date : 21 มิถุนายน 2555 |
Last Update : 21 มิถุนายน 2555 0:26:26 น. |
|
0 comments
|
Counter : 978 Pageviews. |
|
|
|
|
|